BMSC Transfected With Up-regulation MicroRNA-206 In The Treatment Of Bronchopulmonary Dysplasia In Newborn Mice

Objective: Bronchopulmonary dysplasia (BPD) is a chronic lung disease of preterm neonates, and there is no special treatment for it. Our previous researches indicated that bone marrow mesenchymal stem cell therapy is effective in the treatment of Bronchopulmonary dysplasia (BPD) in BPD mice model and the expression of MicroRNA-206 (mir-206) is significantly decreased both in BPD mice model and BPD patients. This article aims to characterize the role of BMSC transfected with up-regulation microRNA-206 in the treatment of bronchopulmonary dysplasia in newborn mice.Method: BPD mice mode was induced by 60% oxygen, beginning at birth. BMSC transfected with miR-206 mimics and blank plasmid were administered on post-natal day 7 and every following weeks via an an intraperitoneal injection (105 cells per animal) until post-natal day 45(or P45). The role of BMSC transfected with up-regulation microRNA-206 in the treatment against BPD was detected by weight, pulmonary coefficient, RAC and pathologic section. The expression of mir-206, FN1 and pulmonary surfactant protein C (SP-C) was using real-time PCR and Immunofluorescence, the expression of TGF-β and IL-6 was using ELISA method.Result: BMSC transfected with miR-206 mimics improve pulmonary architecture, attenuated inflammation and inhibited lung fibrosis in BPD mice compared with blank plasmid group. Up-regulation mir-206 in BMSC decreased the expression of TGF-P and IL-6 in BPD mice model plasma samples, SP-C and FN1 in BPD mice lung tissues.Conclusion: BMSC transfected with up-regulation microRNA-206 is helpful in developing an effective treatment against BPD in newborn mice.